PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...
As part of the collaboration, Secarna will leverage its proprietary, AI-empowered OligoCreator® discovery and development platform to identify promising oligonucleotide candidates, applying both ...
New York, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2023" - https://www ...
The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide ...
Oligonucleotide (oligo) therapies are gaining momentum due to their broad applications in diagnostics, therapeutics, research, and personalized medicine. These treatments offer precise, ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ne ...
September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback